Report Description

Global haemophilia treatment market was valued at USD13906.45 million in 2020 and is forecast to reach USD24205.39 million in 2026 by registering a CAGR of 9.06% during the forecast period. The global haemophilia treatment market is driven by increasing awareness campaigns regarding haemophilia among the population across the globe. Moreover, ongoing attempts in research and development activities for the development of new therapy solutions is positively impacting the growth of the market. Also, surging incidences of bleeding disorders have been observed worldwide, which is further expected to bolster the growth of market over the next few years.

The global haemophilia treatment market is segmented based on type, product, treatment, therapy, company and region. Based on type, the market can be categorized into Haemophilia A, Haemophilia B and Haemophilia C. Generally, the classification depends on the deficiency of coagulation factor present in a patient. Based on that, type A is the most frequent type, and the prevalence rate has been recorded to be four times more than haemophilia type B. In addition to this, majority of existing products are used for treating type A haemophilia, which is contributing to the increasing growth of the segment over the coming years.

Regionally, the market is segregated into North America, Europe, Asia- Pacific, South America and Middle East and Africa. Out of which, North America dominated the global haemophilia treatment market in 2020 owing to increased prevalence of haemophilia A & B in the United States and Canada. Besides this, organic and inorganic strategies of major pharmaceutical companies present in the United States is further contributing to the market growth in the region. Additionally, Asia Pacific region is expected to grow at the fastest rate in the coming years. This high growth can be ascribed to the ease of regulatory policies in Australia and Japan for the approval of drugs for the treatment of haemophilia A. In addition to this, improved funding by public and private players for the improvisation of healthcare facilities in India and China, is further anticipated the drive the market growth in Asia Pacific.

Major players operating in the global haemophilia treatment market include Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, Pfizer, Inc., Takeda Pharmaceutical Company, Sanofi S.A., CSL Behring LLC, BioMarin Pharmaceutical Inc., Octapharma AG, Sangamo Therapeutics Inc., Eagle Pharmaceuticals Inc., Baxter International, Inc., Grifols SA, Biogen Idec, Inc., Alnylam Pharmaceuticals Inc., and others. The companies are adopting new strategies in order to stay competitive in the market. Rising competitiveness is anticipated to drive innovation in the market, therefore helping the industry to solve existing challenges and meet the unmet needs in the market. Besides, these major market players are focusing on new product development, mergers and acquisitions, and business expansion to attain a higher market share.

Years considered for this report:

Historical Years: 2016-2019

Base Year: 2020

Estimated Year: 2021

Forecast Period: 2022–2026

Objective of the Study:

  • To analyze the historical growth in the market size of global haemophilia treatment market from 2016 to 2020.
  • To estimate and forecast the market size of global haemophilia treatment market from 2021 to 2026 and growth rate until 2026.
  • To classify and forecast global haemophilia treatment market based on type, product, treatment, therapy, company and regional distribution.
  • To identify dominant region or segment in the global haemophilia treatment market.
  • To identify drivers and challenges for global haemophilia treatment market.
  • To examine competitive developments such as expansions, new product launches, mergers & acquisitions, etc., in global haemophilia treatment market.
  • To conduct pricing analysis for global haemophilia treatment market.
  • To identify and analyze the profile of leading players operating in global haemophilia treatment market.
  • To identify key sustainable strategies adopted by market players in global haemophilia treatment market.


Click here to download the sample

TechSci Research performed both primary as well as exhaustive secondary research for this study. Initially, TechSci Research sourced a list of companies across the globe. Subsequently, TechSci Research conducted primary research surveys with the identified companies. While interviewing, the respondents were also enquired about their competitors. Through this technique, TechSci Research could include the manufacturers which could not be identified due to the limitations of secondary research. TechSci Research analyzed the hospitals/labs and presence of all major players across the globe.

TechSci Research calculated the market size of global haemophilia treatment market using a bottom-up approach, wherein data for various end-user segments was recorded and forecast for the future years. TechSci Research sourced these values from the industry experts and company representatives and externally validated through analyzing historical data of these product types and applications for getting an appropriate, overall market size. Various secondary sources such as company websites, news articles, press releases, company annual reports, investor presentations and financial reports were also studied by TechSci Research.

Key Target Audience:

  • Haemophilia treatment facilities, companies and other stakeholders
  • Government bodies such as regulating authorities and policy makers
  • Organizations, forums and alliances related to haemophilia treatment
  • Market research and consulting firms

The study is useful in providing answers to several critical questions that are important for the industry stakeholders such as companies, partners, end users, etc., besides allowing them in strategizing investments and capitalizing on market opportunities.

Report Scope:

In this report, global haemophilia treatment market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

  • Global Haemophilia Treatment Market, By Type:
    • Haemophilia A
    • Haemophilia B
    • Haemophilia C
  • Global Haemophilia Treatment Market, By Product:
    • Recombinant Coagulation Factor Concentrates
    • Plasma Derived Coagulation Factor Concentrate
    • Desmopressin
    • Antifibrinolytics Agents
  • Global Haemophilia Treatment Market, By Treatment:
    • On-demand
    • Prophylaxis
  • Global Haemophilia Treatment Market, By End-user:
    • Replacement Therapy
    • ITI therapy
    • Gene Therapy
  • Global Haemophilia Treatment Market, By Region:
    • North America
      • United States
      • Canada
      • Mexico
    • Europe
      • Germany
      • United Kingdom
      • France
      • Italy
      • Spain
    • Asia-Pacific
      • India
      • China
      • Japan
      • Australia
      • South Korea
    • South America
      • Brazil
      • Argentina
      • Colombia
    • Middle East & Africa
      • Saudi Arabia
      • UAE
      • South Africa

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in global haemophilia treatment market.

Available Customizations:

With the given market data, TechSci Research offers customizations according to a company’s specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five)

Table of content

1.    Product Overview

2.    Research Methodology

3.    Impact of COVID-19 on Global Haemophilia Treatment Market

4.    Executive Summary

5.    Voice of Customer

5.1.  Brand Awareness

5.2.  Unmet Needs & Challenges

5.3.  Factors Influencing Drug Purchase

6.    Global Haemophilia Treatment Market Outlook

6.1.  Market Size & Forecast

6.1.1.     By Value

6.2.  Market Share & Forecast

6.2.1.     By Type (Haemophilia A, Haemophilia B, Haemophilia C)

6.2.2.     By Product (Recombinant Coagulation Factor Concentrates, Plasma Derived Coagulation Factor Concentrate, Desmopressin, Antifibrinolytics Agents)

6.2.3.     By Treatment (On-demand and Prophylaxis)

6.2.4.     By Therapy (Replacement Therapy, ITI Therapy and Gene Therapy)

6.2.5.     By Company (2020)

6.2.6.     By Region

6.3.  Product Market Map

7.    North America Haemophilia Treatment Market Outlook

7.1.  Market Size & Forecast          

7.1.1.     By Value

7.2.  Market Share & Forecast

7.2.1.     By Type

7.2.2.     By Product

7.2.3.     By Treatment

7.2.4.     By Therapy

7.2.5.     By Country

7.3.  North America: Country Analysis

7.3.1.     United States Haemophilia Treatment Market Outlook

7.3.1.1.         Market Size & Forecast

7.3.1.1.1.             By Value

7.3.1.2.         Market Share & Forecast

7.3.1.2.1.             By Type

7.3.1.2.2.             By Product

7.3.1.2.3.             By Treatment

7.3.1.2.4.             By Therapy

7.3.2.     Canada Haemophilia Treatment Market Outlook

7.3.2.1.         Market Size & Forecast

7.3.2.1.1.             By Value

7.3.2.2.         Market Share & Forecast

7.3.2.2.1.             By Type

7.3.2.2.2.             By Product

7.3.2.2.3.             By Treatment

7.3.2.2.4.             By Therapy

7.3.3.     Mexico Haemophilia Treatment Market Outlook

7.3.3.1.         Market Size & Forecast

7.3.3.1.1.             By Value

7.3.3.2.         Market Share & Forecast

7.3.3.2.1.             By Type

7.3.3.2.2.             By Product

7.3.3.2.3.             By Treatment

7.3.3.2.4.             By Therapy

8.    Europe Haemophilia Treatment Market Outlook

8.1.  Market Size & Forecast          

8.1.1.     By Value

8.2.  Market Share & Forecast

8.2.1.     By Type

8.2.2.     By Product

8.2.3.     By Treatment

8.2.4.     By Therapy

8.2.5.     By Country

8.3.  Europe: Country Analysis

8.3.1.     Germany Haemophilia Treatment Market Outlook

8.3.1.1.         Market Size & Forecast

8.3.1.1.1.             By Value

8.3.1.2.         Market Share & Forecast

8.3.1.2.1.             By Type

8.3.1.2.2.             By Product

8.3.1.2.3.             By Treatment

8.3.1.2.4.             By Therapy

8.3.2.     United Kingdom Haemophilia Treatment Market Outlook

8.3.2.1.         Market Size & Forecast

8.3.2.1.1.             By Value

8.3.2.2.         Market Share & Forecast

8.3.2.2.1.             By Type

8.3.2.2.2.             By Product

8.3.2.2.3.             By Treatment

8.3.2.2.4.             By Therapy

8.3.3.     France Haemophilia Treatment Market Outlook

8.3.3.1.         Market Size & Forecast

8.3.3.1.1.             By Value

8.3.3.2.         Market Share & Forecast

8.3.3.2.1.             By Type

8.3.3.2.2.             By Product

8.3.3.2.3.             By Treatment

8.3.3.2.4.             By Therapy

8.3.4.     Italy Haemophilia Treatment Market Outlook

8.3.4.1.         Market Size & Forecast

8.3.4.1.1.             By Value

8.3.4.2.         Market Share & Forecast

8.3.4.2.1.             By Type

8.3.4.2.2.             By Product

8.3.4.2.3.             By Treatment

8.3.4.2.4.             By Therapy

8.3.5.     Spain Haemophilia Treatment Market Outlook

8.3.5.1.         Market Size & Forecast

8.3.5.1.1.             By Value

8.3.5.2.         Market Share & Forecast

8.3.5.2.1.             By Type

8.3.5.2.2.             By Product

8.3.5.2.3.             By Treatment

8.3.5.2.4.             By Therapy

9.    Asia-Pacific Haemophilia Treatment Market Outlook

9.1.  Market Size & Forecast          

9.1.1.     By Value

9.2.  Market Share & Forecast

9.2.1.     By Type

9.2.2.     By Product

9.2.3.     By Treatment

9.2.4.     By Therapy

9.2.5.     By Country

9.3.  Asia-Pacific: Country Analysis

9.3.1.     India Haemophilia Treatment Market Outlook

9.3.1.1.         Market Size & Forecast

9.3.1.1.1.             By Value

9.3.1.2.         Market Share & Forecast

9.3.1.2.1.             By Type

9.3.1.2.2.             By Product

9.3.1.2.3.             By Treatment

9.3.1.2.4.             By Therapy

9.3.2.     China Haemophilia Treatment Market Outlook

9.3.2.1.         Market Size & Forecast

9.3.2.1.1.             By Value

9.3.2.2.         Market Share & Forecast

9.3.2.2.1.             By Type

9.3.2.2.2.             By Product

9.3.2.2.3.             By Treatment

9.3.2.2.4.             By Therapy

9.3.3.     Japan Haemophilia Treatment Market Outlook

9.3.3.1.         Market Size & Forecast

9.3.3.1.1.             By Value

9.3.3.2.         Market Share & Forecast

9.3.3.2.1.             By Type

9.3.3.2.2.             By Product

9.3.3.2.3.             By Treatment

9.3.3.2.4.             By Therapy

9.3.4.     Australia Haemophilia Treatment Market Outlook

9.3.4.1.         Market Size & Forecast

9.3.4.1.1.             By Value

9.3.4.2.         Market Share & Forecast

9.3.4.2.1.             By Type

9.3.4.2.2.             By Product

9.3.4.2.3.             By Treatment

9.3.4.2.4.             By Therapy

9.3.5.     South Korea Haemophilia Treatment Market Outlook

9.3.5.1.         Market Size & Forecast

9.3.5.1.1.             By Value

9.3.5.2.         Market Share & Forecast

9.3.5.2.1.             By Type

9.3.5.2.2.             By Product

9.3.5.2.3.             By Treatment

9.3.5.2.4.             By Therapy

10.  South America Haemophilia Treatment Market Outlook

10.1.              Market Size & Forecast

10.1.1.  By Value

10.2.              Market Share & Forecast

10.2.1.  By Type

10.2.2.  By Product

10.2.3.  By Treatment

10.2.4.  By Therapy

10.2.5.  By Country

10.3.              South America: Country Analysis

10.3.1.  Brazil Haemophilia Treatment Market Outlook

10.3.1.1.      Market Size & Forecast

10.3.1.1.1.           By Value

10.3.1.2.      Market Share & Forecast

10.3.1.2.1.           By Type

10.3.1.2.2.           By Product

10.3.1.2.3.           By Treatment

10.3.1.2.4.           By Therapy

10.3.2.  Argentina Haemophilia Treatment Market Outlook

10.3.2.1.      Market Size & Forecast

10.3.2.1.1.           By Value

10.3.2.2.      Market Share & Forecast

10.3.2.2.1.           By Type

10.3.2.2.2.           By Product

10.3.2.2.3.           By Treatment

10.3.2.2.4.           By Therapy

10.3.3.  Colombia Haemophilia Treatment Market Outlook

10.3.3.1.      Market Size & Forecast

10.3.3.1.1.           By Value

10.3.3.2.      Market Share & Forecast

10.3.3.2.1.           By Type

10.3.3.2.2.           By Product

10.3.3.2.3.           By Treatment

10.3.3.2.4.           By Therapy

11.  Middle East and Africa Haemophilia Treatment Market Outlook

11.1.              Market Size & Forecast

11.1.1.  By Value

11.2.              Market Share & Forecast

11.2.1.  By Type

11.2.2.  By Product

11.2.3.  By Treatment

11.2.4.  By Therapy

11.2.5.  By Country

11.3.              MEA: Country Analysis

11.3.1.  Saudi Arabia Haemophilia Treatment Market Outlook

11.3.1.1.      Market Size & Forecast

11.3.1.1.1.           By Value

11.3.1.2.      Market Share & Forecast

11.3.1.2.1.           By Type

11.3.1.2.2.           By Product

11.3.1.2.3.           By Treatment

11.3.1.2.4.           By Therapy

11.3.2.  UAE Haemophilia Treatment Market Outlook

11.3.2.1.      Market Size & Forecast

11.3.2.1.1.           By Value

11.3.2.2.      Market Share & Forecast

11.3.2.2.1.           By Type

11.3.2.2.2.           By Product

11.3.2.2.3.           By Treatment

11.3.2.2.4.           By Therapy

11.3.3.  South Africa Haemophilia Treatment Market Outlook

11.3.3.1.      Market Size & Forecast

11.3.3.1.1.           By Value

11.3.3.2.      Market Share & Forecast

11.3.3.2.1.           By Type

11.3.3.2.2.           By Product

11.3.3.2.3.           By Treatment

11.3.3.2.4.           By Therapy

12.  Market Dynamics

12.1. Drivers

12.2. Challenges

13.  Market Trends & Developments

14.  Competitive Landscape

14.1. Novo Nordisk A/S

14.2. F. Hoffmann-La Roche AG

14.3. Bayer AG

14.4. Pfizer, Inc.

14.5. Takeda Pharmaceutical Company

14.6. Sanofi S.A.

14.7. CSL Behring LLC

14.8. BioMarin Pharmaceutical Inc.

14.9. Octapharma AG

14.10. Sangamo Therapeutics Inc.

14.11. Eagle Pharmaceuticals Inc.

14.12. Baxter International, Inc.

14.13. Grifols SA

14.14. Biogen Idec, Inc.

14.15. Alnylam Pharmaceuticals Inc.

15.  Strategic Recommendations

16.  About Us & Disclaimer

Figures and Tables

Figure 1: Global Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 2: Global Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 3: Global Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 4: Global Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 5: Global Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 6: Global Haemophilia Treatment Market Share, By Company, 2020

Figure 7: Global Haemophilia Treatment Market Share, By Region, By Value, 2016-2026F

Figure 8: Global Haemophilia Treatment Product Market Map, By Value, 2016-2026F

Figure 9: North America Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 10: North America Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 11: North America Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 12: North America Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 13: North America Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 14: North America Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F

Figure 15: United States Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 16: United States Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 17: United States Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 18: United States Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 19: United States Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 20: Canada Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 21: Canada Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 22: Canada Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 23: Canada Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 24: Canada Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 25: Mexico Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 26: Mexico Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 27: Mexico Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 28: Mexico Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 29: Mexico Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 30: Europe Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 31: Europe Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 32: Europe Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 33: Europe Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 34: Europe Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 35: Europe Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F

Figure 36: Germany Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 37: Germany Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 38: Germany Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 39: Germany Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 40: Germany Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 41: United Kingdom Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 42: United Kingdom Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 43: United Kingdom Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 44: United Kingdom Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 45: United Kingdom Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 46: France Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 47: France Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 48: France Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 49: France Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 50: France Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 51: Italy Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 52: Italy Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 53: Italy Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 54: Italy Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 55: Italy Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 56: Spain Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 57: Spain Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 58: Spain Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 59: Spain Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 60: Spain Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 61: Asia Pacific Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 62: Asia Pacific Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 63: Asia Pacific Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 64: Asia Pacific Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 65: Asia Pacific Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 66: Asia Pacific Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F

Figure 67: India Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 68: India Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 69: India Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 70: India Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 71: India Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 72: China Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 73: China Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 74: China Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 75: China Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 76: China Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 77: Japan Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 78: Japan Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 79: Japan Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 80: Japan Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 81: Japan Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 82: Australia Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 83: Australia Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 84: Australia Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 85: Australia Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 86: Australia Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 87: South Korea Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 88: South Korea Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 89: South Korea Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 90: South Korea Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 91: South Korea Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 92: South America Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 93: South America Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 94: South America Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 95: South America Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 96: South America Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F

Figure 97: Brazil Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 98: Brazil Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 99: Brazil Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 100: Brazil Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 101: Brazil Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 102: Argentina Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 103: Argentina Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 104: Argentina Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 105: Argentina Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 106: Argentina Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 107: Colombia Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 108: Colombia Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 109: Colombia Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 110: Colombia Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 111: Colombia Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 112: Middle East & Africa Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 113: Middle East & Africa Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 114: Middle East & Africa Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 115: Middle East & Africa Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 116: Middle East & Africa Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 117: Middle East & Africa Haemophilia Treatment Market Share, By Country, By Value, 2016-2026F

Figure 118: Saudi Arabia Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 119: Saudi Arabia Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 120: Saudi Arabia Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 121: Saudi Arabia Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 122: Saudi Arabia Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 123: UAE Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 124: UAE Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 125: UAE Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 126: UAE Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 127: UAE Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Figure 128: South Africa Haemophilia Treatment Market Size, By Value (USD Million), 2016-2026F

Figure 129: South Africa Haemophilia Treatment Market Share, By Type, By Value, 2016-2026F

Figure 130: South Africa Haemophilia Treatment Market Share, By Product, By Value, 2016-2026F

Figure 131: South Africa Haemophilia Treatment Market Share, By Treatment, By Value, 2016-2026F

Figure 132: South Africa Haemophilia Treatment Market Share, By Therapy, By Value, 2016-2026F

Frequently asked questions

down-arrow

Based on product, the market is fragmented into plasma derived coagulation factor concentrate, recombinant coagulation factor concentrates, desmopressin, and antifibrinolytics agents. The recombinant coagulation factor concentrates segment dominated the market in terms of largest market share in 2020. Increase in production of recombinant factor concentrates to treat haemophilia along with its better outcome as compared to plasma derived coagulation factor concentrate are the reasons for its dominance.

down-arrow

Companies such as Novo Nordisk A/S, F. Hoffmann-La Roche AG, Bayer AG, Pfizer, Inc., Takeda Pharmaceutical Company, Sanofi S.A., CSL Behring LLC, Octapharma AG, among others are the top companies for haemophilia treatment.

down-arrow

Factors such as the increasing number of haemophilic patients across the globe, upsurge in the use of prophylactic treatment for haemophilia and supportive initiatives plan by governments are expected to drive the global haemophilia treatment market.

down-arrow

Based on treatment, the Haemophilia Treatment market is fragmented into on-demand and prophylaxis. The prophylaxis treatment is projected to register the highest growth in the years to come. High efficiency and better end results coupled with preference for long-term prophylaxis treatment to prevent chronic arthropathy and joint bleeding in patients with severe haemophilia are the driving factors.

profile

Sakshi Bajaal

Business Consultant
Press Release

Haemophilia Treatment Market to Surpass USD 24205.39 by 2026

Sep, 2021

Increasing number of haemophilic patients worldwide and increased diagnosis rate across the globe to drive global haemophilia treatment market